Literature DB >> 8793008

Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins.

W Keulen1, C Boucher, B Berkhout.   

Abstract

The enzyme reverse transcriptase (RT) plays a fundamental role in the replication of the human immunodeficiency virus type 1 (HIV-1) and several antiviral agents that target this key enzyme have been developed. Unfortunately, treatment of patients with RT inhibitors results in the appearance of drug-resistant variants with specific mutations in the RT protein. We hypothesized that if "difficult' resistance mutations (e.g. transversions/double-hits) are consistently observed at certain positions, it is likely that "easier' nucleotide substitutions (transitions/single-hits) at that codon do not result in a drug-resistant and/or active RT enzyme. In this study, we examined codon changes involved in RT drug resistance against nucleoside and non-nucleoside inhibitors and listed all easier substitutions, which apparently were not selected, either due to reduced enzyme RT activity or lack of drug resistance. These predictions on the requirements for resistance were confirmed by published mutational data on RT variants. We also propose that differences in mutation type can explain the order of appearance of substitutions in case multiple amino acid changes are required for optimal fitness. Differences in mutation pattern have been reported for drug-resistant HIV-1 variants selected in tissue culture compared with variants found in treated patients. In contrast to the in vivo situation, a relatively small population size is handled in in vitro tissue culture systems and this may limit the chances of creating a resistance mutation. Indeed, inspection of the codon changes indicates that the in vitro culture system is more strongly biased towards the relatively easy nucleotide substitutions. These results suggest that the nucleotide substitution pattern can provide important information on RT drug resistance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8793008     DOI: 10.1016/0166-3542(96)00944-8

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  36 in total

Review 1.  HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms.

Authors:  Atze T Das; Ben Berkhout
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-06-27       Impact factor: 6.237

Review 2.  Drug resistance and antiretroviral drug development.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  J Antimicrob Chemother       Date:  2005-04-21       Impact factor: 5.790

3.  Substitutions in the reverse transcriptase and protease genes of HIV-1 subtype B in untreated individuals and patients treated with antiretroviral drugs.

Authors:  Dan Turner; Bluma Brenner; Daniela Mosis; Chen Liang; Mark A Wainberg
Journal:  MedGenMed       Date:  2005-03-24

4.  The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS.

Authors:  Elena Herrera-Carrillo; Ying Poi Liu; Ben Berkhout
Journal:  Mol Ther       Date:  2013-12-12       Impact factor: 11.454

5.  Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil.

Authors:  A Tanuri; A C Vicente; K Otsuki; C A Ramos; O C Ferreira; M Schechter; L M Janini; D Pieniazek; M A Rayfield
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

6.  Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.

Authors:  S Yerly; A Rakik; S K De Loes; B Hirschel; D Descamps; F Brun-Vézinet; L Perrin
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

7.  Forced evolution of a regulatory RNA helix in the HIV-1 genome.

Authors:  B Berkhout; B Klaver; A T Das
Journal:  Nucleic Acids Res       Date:  1997-03-01       Impact factor: 16.971

8.  Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity.

Authors:  Diane N Singhroy; Mark A Wainberg; Thibault Mesplède
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

9.  The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy.

Authors:  E Herrera-Carrillo; B Berkhout
Journal:  Gene Ther       Date:  2015-02-26       Impact factor: 5.250

10.  Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs.

Authors:  Dan Turner; Bluma Brenner; Daniela Moisi; Chen Liang; Mark A Wainberg
Journal:  J Int AIDS Soc       Date:  2005-03-23       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.